Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BOS172767 in Healthy Subjects
NCT03464058Phase 1Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BOS172767 enantiomer E1 or E2 in psoriasis (13 arms), sponsored by Boston Pharmaceuticals. Primary endpoints: Treatment-Emergent Serious Adverse Events up to 33 weeks, Treatment-Emergent Adverse Events up to 33 weeks and 5 more. Started Mar 2018; status: completed.
02
Drugs
BOS172767 enantiomer E1 or E2
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03464058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464058.